Development of novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives for inhibiting the catalytic activity of botulinum neurotoxins type B and F: in silico, in vitro & in vivo evaluation
- 13 May 2026
- journal article
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (9) , 4257-4273
Abstract
Botulinum neurotoxins (BoNTs) are the most pernicious toxin and category 'A' bioterrorism agent, responsible for 'botulism', a rare but fatal disease. Toxins are divided into seven toxinotypes from A-G, where A, B, E, and F are accountable for human botulism. The available treatment strategies are inadequate and ineffective for post-neuronal intoxication. We report novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid derivatives targetingthe catalytic site of VAMP-acting serotypes (BoNT/B and F). Inhibitory potential of the synthesized compounds was studied using a framework of in silico and experimental approaches. Inhibitory activity and binding affinity were evaluated using substrate-based cleavage and SPR assays. Compound efficacy was tested in mice through pre-mixed, prophylactic, and therapeutic strategies. Molecular dynamics simulations analyzed binding interactions, structural fluctuations, and complex stability. Endopeptidase assay revealed that the selected compounds displayed ≥ 80% inhibition of BoNT/B and F catalytic activity, with IC50 values ranging from 17.58 to 34.05 µM. SPR analysis displayed binding affinity of these molecules ranging from 8.13E-06 to 7.69E-04 for both the proteins. In the mouse bioassay, the selected molecules displayed complete protection and extension in survival of up to 20-fold. MD simulation study supported the experimental finding, revealing key interactions with HExxH and other active site residues forming stable conformation throughout the simulation time. Among them, compounds A15 and A36 were predicted to be more effective inhibitors of BoNT/B and F serotypes, respectively. These findings could lay a promising way for the development of novel therapeutics by reducing disease severity, enhancing survivability, and recovery where no post-exposure therapy presently available.Keywords
This publication has 37 references indexed in Scilit:
- Targeting the Enzymatic Site of Botulinum Neurotoxin Type E With 8‐Hydroxyquinolinol–Based Inhibitors: In Silico, In Vitro, and In Vivo EvaluationDrug Development Research, 2025
- Novel 2-[(8-hydroxyquinolin-7-yl)(phenyl)methylamino]benzoic acid analogs targeting the active site of botulinum neurotoxins: designing, synthesis, and biological evaluationMedicinal Chemistry Research, 2024
- Designing, synthesis and evaluation of derived analogues of selected small molecule non-peptidic inhibitors against serotype BoNT/ FToxicon, 2022
- Targeted 8-hydroxyquinoline fragment based small molecule drug discovery against neglected botulinum neurotoxin type FBioorganic Chemistry, 2019
- High level expression and immunochemical characterization of botulinum neurotoxin type F light chainProtein Expression and Purification, 2018
- Identification of small molecule inhibitors of botulinum neurotoxin serotype E via footprint similarityBioorganic & Medicinal Chemistry, 2016
- Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitorsToxicon, 2015
- Genetic Diversity Within Clostridium botulinum Serotypes, Botulinum Neurotoxin Gene Clusters and Toxin Subtypes2012
- Botulinal neurotoxins: revival of an old killerCurrent Opinion in Pharmacology, 2005
- Botulinum Toxin as a Biological WeaponJAMA, 2001